

DEPARTMENT OF HEALTH AND HUMAN SERVICES
 PUBLIC HEALTH SERVICE
 FOOD AND DRUG ADMINISTRATION
**ESTABLISHMENT REGISTRATION AND LISTING FOR HUMAN CELLS, TISSUES,
 AND CELLULAR AND TISSUE-BASED PRODUCTS (HCT/Ps)**
 (See reverse side for instructions)

1. REGISTRATION NUMBER
 (FDA Establishment Identifier)
 FEI: 3005357288

See Instructions for OMB Statement. FORM APPROVED: OMB No.0910-0543. Expiration Date: 3/31/2017

2. REASON FOR SUBMISSION VALIDATION--FOR FDA USE ONLY 1
 a. INITIAL REGISTRATION / LISTING VALIDATED BY FDA:25-NOV-2015
 b. ANNUAL REGISTRATION / LISTING DISTRICT: Atlanta
 c. CHANGE IN INFORMATION PRINTED BY FDA:03-DEC-2015
 d. INACTIVE

PART I - ESTABLISHMENT INFORMATION

3. OTHER FDA REGISTRATIONS

- a. BLOOD FDA 2830 NO.
 b. DEVICES FDA 2891 NO. FEI: 3005357288
 c. DRUG FDA 2856 NO.

4. PHYSICAL LOCATION (Include legal name, number and street, city, state, country, and post office code)

Ocular Systems, LLC
 101 North Chestnut Street
 Suite 303
 Winston-Salem, North Carolina 27101

- a. PHONE 336-784-4603 EXT
 b. SATELLITE RECOVERY ESTABLISHMENT
 (MANUFACTURING ESTABLISHMENT FEI NO. _____)
 c. TESTING FOR MICRO-ORGANISMS ONLY

5. ENTER CORRECTIONS TO ITEM 4

6. MAILING ADDRESS OF REPORTING OFFICIAL (Include institution name if applicable, number and street, city, state, country, and post office code)

Ocular Systems, LLC
 Attn: Scott Carlisle
 101 North Chestnut Street
 Suite 303
 Winston-Salem, North Carolina 27101

- a. PHONE 336-784-4603 EXT
7. ENTER CORRECTIONS TO ITEM 6 b. PHONE

8. U.S. AGENT

a. E-MAIL
9. REPORTING OFFICIAL'S SIGNATURE

- a. TYPED NAME Scott Carlisle
 b. E-MAIL scarlisle@ocularsystemsinc.com
 c. TITLE Quality Assurance Director
 d. DATE 24-NOV-2015

PART II - PRODUCT INFORMATION

10. ESTABLISHMENT FUNCTIONS AND TYPES OF HCT / Ps

Types of HCT / Ps	Establishment Functions							14. PROPRIETARY NAME(S)	
	Recover	Screen	Test	Package	Process	Store	Label		Distribute
a. Bone									
b. Cartilage									
c. Cornea				X	X	X	X	X	X
d. Dura Mater									
e. Embryo									
	SIP								
	<input type="checkbox"/> Directed								
	<input type="checkbox"/> Anonymous								
f. Fascia									
g. Heart Valve									
h. Ligament									
i. Oocyte									
	SIP								
	<input type="checkbox"/> Directed								
	<input type="checkbox"/> Anonymous								
j. Pericardium									
k. Peripheral Blood Stem									
	<input type="checkbox"/> Autologous								
	<input type="checkbox"/> Family Related								
	<input type="checkbox"/> Allogeneic								
l. Sclera									
m. Semen									
	SIP								
	<input type="checkbox"/> Directed								
	<input type="checkbox"/> Anonymous								
n. Skin									
o. Somatic Cell Therapy Products									
	<input type="checkbox"/> Autologous								
	<input type="checkbox"/> Family Related								
	<input type="checkbox"/> Allogeneic								
p. Tendon									
q. Umbilical Cord Blood									
	<input type="checkbox"/> Autologous								
	<input type="checkbox"/> Family Related								
	<input type="checkbox"/> Allogeneic								
r. Vascular Graft									
s.									
t.									
u.									
v.									

11. HCT/Ps DESCRIBED IN 21 CFR 1271.10
 12. HCT/Ps REGULATED AS MEDICAL DEVICES
 13. HCT/Ps REGULATED AS BIOLOGICAL DRUGS